| |  |
| |
| | R1, R2 and R3 form DNA-binding domain, TA - transactivation domain, CR - conserved region (the area of homology with c-Myb), RD - regulatory domain. |
| |
| Description | 704 amino acids, 93kDa protein.
R1, R2, R3 - three repeats 50 amino acids long, R2 and R3 contain HTH (helix-turn-helix) motives with unconventional turns required for DNA-binding activity, R1 serves as a DNA/protein complex stabilizer; TA contains acidic amino acids and is responsible for transcriptional activation; RD is responsible for repression of transactivation function of B-MYB. |
| Expression | Widely expressed, expression is very high in proliferative cells, embryonic cells, haematopoietic progenitor cells. |
| Localisation | Nucleus. |
| Function | Transcription factor required for cell proliferation, cell cycle progression, chromosomal stability and differentiation. B-MYB knockout mice die at E4.5-E6.5 due to early developmental arrest. |
| Homology | B-MYB is a member of MYB transcription factors family, which includes C-MYB and A-MYB, with high homology within TA and RD regions. DNA-binding domain is almost identical with that of A-MYB and C-MYB and conserved between mouse, human, chicken and drosophila. |
| Requirement of b-myb function for survival and differentiative potential of human neuroblastoma cells. |
| Raschell G, Negroni A, Sala A, Pucci S, Romeo A, Calabretta B. |
| J Biol Chem. 1995 Apr 14;270(15):8540-5. |
| PMID 7721753 |
| |
| Mybl2 (Bmyb) maps to mouse chromosome 2 and human chromosome 20q13.1. |
| Noben-Trauth K, Copeland NG, Gilbert DJ, Jenkins NA, Sonoda G, Testa JR, Klempnauer KH. |
| Genomics. 1996 Aug 1;35(3):610-2. |
| PMID 8812502 |
| |
| The myb gene family in cell growth, differentiation and apoptosis. |
| Oh IH, Reddy EP. |
| Oncogene. 1999 May 13;18(19):3017-33.(Review). |
| PMID 10378697 |
| |
| Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. |
| Raschella G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonni GP, De Bernardi B, Calabretta B. |
| Cancer Res. 1999 Jul 15;59(14):3365-8. |
| PMID 10416595 |
| |
| B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments. |
| Sala A, Watson R. |
| J Cell Physiol. 1999 Jun;179(3):245-50.(Review). |
| PMID 10228942 |
| |
| B-myb is required for inner cell mass formation at an early stage of development. |
| Tanaka Y, Patestos NP, Maekawa T, Ishii S. |
| J Biol Chem. 1999 Oct 1;274(40):28067-70. |
| PMID 10497154 |
| |
| B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival. |
| Schwab R, Caccamo A, Bettuzzi S, Anderson J, Sala A. |
| Blood Cells Mol Dis 2007; 39(3):263-71. Epub 2007 Jun 27. |
| PMID 17588787 |
| |
| Activation of B-Myb by E2F1 in hepatocellular carcinoma. |
| Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Inazawa J, Okanoue T. |
| Hepatol Res. 2008; 38(9): 886-95. |
| PMID 18624722 |
| |
| Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk. |
| Schwab R, Bussolari R, Corvetta D, Chayka O, Santilli G, Kwok JM-M, Amorotti GF, Tonini P, Iacoviello L, Bertorelle R, Menin C, Hubank M, Calabretta B, Sala A. |
| Oncogene 2008; 27(20): 2929-33. |
| PMID 18026132 |
| |
